Abstract:Background: The role of RASGRF2 has been verified in the development of various cancers. However, its roles in stomach adenocarcinoma (STAD) are still under investigation. Methods: RASGRF2 transcript-level data and the associated clinical information from patients with STAD were extracted from The Cancer Genome Atlas (TCGA). Diagnostic and prognostic values of RASGRF2 were analyzed using receiver-operator characteristics (ROC) analysis, correlation analysis, and survival analysis in conjunction with a prognostic model. In addition, gene expression profiles, differentially-expressed genes for co-varying expression, and a differential expressed genes (DEG) protein-protein interaction network for influential nodes were also analyzed. To identify the molecular role of RASGRF2 in STAD, gene ontology (GO) term, Kyoto Encyclopedia of Genes and Genomes (KEGG) biological pathway, and gene set enrichment analysis (GSEA)-mediated functional module enrichment analyses were conducted. The relationship between RASGRF2 and gene signature-based predicted immune cell infiltration patterns were also investigated. To validate the bioinformatic findings, RASGRF2 protein expression was investigated in vitro using western blot and immunohistochemistry. Furthermore, relationships among RASGRF2 protein expression, clinicopathologic characteristics, and patient survival were analyzed. Results: Bioinformatic analysis revealed a significantly higher RASGRF2 transcript level in STAD tissue, which was positively associated with the T stage, histological type, histological grade, and TP53 status. Moreover, the RASGRF2 transcript level indicated poor overall survival in STAD patients (hazard ratio = 1.47, P = 0.023). Multivariate Cox regression analysis showed that primary therapy outcome, age, and RASGRF2 transcript level were independent prognostic factors for survival, and the C-index of a nomogram was 0.695. Additionally, 159 genes were differentially expressed according to RASGRF2 transcript levels; 15 exhibited co-varying expression, and 13 were identified as influential nodes. The DEG-list was significantly enriched for several GO terms, biological pathways, and functional modules, including MAPK, RAS, ERK, and immunoregulatory pathways. RASGRF2 transcript levels were significantly positively correlated with infiltration levels of Tem, Macrophages, pDCs, and NK cells. Validation analysis showed similar results for the RASGRF2 protein expression level in both in vitro analyses. Conclusion: Bioinformatic predictions combined with in vitro validation suggest that RASGRF2 plays diagnostic and prognostic roles and serves as a negative protective molecular factor in STAD patients.

Dopamine Receptor D2 is Correlated with Gastric Cancer Prognosis.

Dystroglycan is Associated with Tumor Progression and Patient Survival in Gastric Cancer

Dopamine D2 Receptor Suppresses Gastric Cancer Cell Invasion and Migration Via Inhibition of EGFR/AKT/MMP-13 Pathway.

[Study on Novel Gene GDDR Related to Gastric Cancer].

Dopamine Receptor D3 is Related to Prognosis in Human Hepatocellular Carcinoma and Inhibits Tumor Growth.

Decreased Levels Of Active Smad2 Correlate With Poor Prognosis In Gastric Cancer

ROR alpha and REV-ERB alpha are Associated With Clinicopathological Parameters and are Independent Biomarkers of Prognosis in Gastric Cancer

High Expression of ERK-related RASGRF2 Predicts Poor Prognosis in Patients with Stomach Adenocarcinoma and Correlates with M2 Macrophage

Relationship Between the DPD and TS Mrna Expression and the Response to S-1-Based Chemotherapy and Prognosis in Patients with Advanced Gastric Cancer

NDRG4 in Gastric Cancer Determines Tumor Cell Proliferation and Clinical Outcome.

Death Receptor 5 Promotes Tumor Progression in Gastric Cancer.

Expression and Clinical Significance of Gastric Dramatic Down-Related Gene in Gastric Cancer and Precancerous Lesions

The NDRG1 Expression and the Prognosis in Patients of Gastric Carcinoma

CD3D Is an Independent Prognostic Factor and Correlates With Immune Infiltration in Gastric Cancer

The Role of Dopamine in Gastric Cancer—A Systematic Review of the Pathogenesis Phenomena Developments

Upregulation of Programmed Death Ligand 1 and Epidermal Growth Factor Receptor is Associated with Poor Prognosis in Gastric Cancer

Increased dopamine and its receptor dopamine receptor D1 promote tumor growth in human hepatocellular carcinoma

AGR2 is associated with gastric cancer progression and poor survival.

Study on expression of NDRG2 protein in gastric cancer tissue

A novel molecular marker for early detection and evaluating prognosis of gastric cancer: N-myc downstream regulated gene-1 (NDRG1).

Expression of Orphan Nuclear Receptor NR4A2 in Gastric Cancer Cells Confers Chemoresistance and Predicts an Unfavorable Postoperative Survival of Gastric Cancer Patients with Chemotherapy.